Multiple myeloma trials in Czechia

In Czechia 23 Also abroad 703

23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Brno, Hradec Králové, Ostrava
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Brno, Hradec Králové, Ostrava, Prague
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Brno, Novy Hradec Kralove, Olomouc, Ostrava, Plzen 23, Prague
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Brno, Hradec Králové, Ostrava, Pilsen, Prague
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Brno, Prague
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Brno, Hradec Králové, Ostrava, Prague
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Brno, Olomouc, Prague
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Ostrava
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 3Taking people
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Where
Brno, Hradec Králové, Ostrava, Plzen 23, Prague
Age
18 years and over
People
206 worldwide
Run by
Janssen Cilag International
See details and how to join2025-523815-12-00 · EU 2025-523815-12-00
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Brno, Ostrava, Prague
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
No phaseTaking people
Early Detection and Screening of Hematological Malignancies - SANGUINE
Where
Olomouc
Age
18 years and over
People
3,000 worldwide
Run by
JaxBio Ltd
See details and how to joinNCT05735704
Phase 3Taking people
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Where
Brno, Hradec Králové, Ostrava, Plzen 23, Prague
Age
18 years and over
People
423 worldwide
Run by
Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Hradec Králové, Ostrova, Prague
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Ostrava, Prague
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Ostrava, Plzen 23, Praha 10
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Brno, Hradec Králové, Ostrava, Plzen-Lochotin, Prague
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Brno, Novy Hradec Kralove, Olomouc, Ostrava, Plzen 23, Prague
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Brno, Olomouc, Prague 10, Prague 2
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Brno, Ostrava
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Ostrava, Prague
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Brno, Hradec Králové, Olomouc, Ostrava, Plzen 23
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Pilsen, Prague
Age
18 years and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757
No phaseTaking people
European Myeloma Network (EMN) Sample Project
Where
Havířov, Nový Jičín, Olomouc, Opava, Ostrava, Pelhřimov, Prague
Age
18 years and over
People
6,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06237803